on IKONISYS (EPA:ALIKO)
Ikonisys SA Reports Increased Revenues and Developments in 2025
Ikonisys SA, now trading as Aliko Scientific, announced a 52.6% revenue increase to €1.64 million for 2025, aided by Hospitex's full-year contribution and the rollout of Aliko Scientific’s offerings. The company reduced its EBITDA loss by 32.9% to €1.14 million.
Key developments include the US patent for ACTA, the launch of Urine24, and a distribution deal with Menarini Diagnostics. CEO Francesco Trisolini highlighted the transformation under the Aliko brand as a significant step towards building an integrated oncology diagnostics platform.
The 2025 financial statements reflected growth, but also a net loss increase to €4.20 million due to accelerated amortization charges. Cash reserves rose significantly to €1.03 million by year-end.
Aliko's strategy emphasizes expanding international distribution, integrating products, and boosting recurring revenues from consumables and services. The 2025 Annual Financial Report is available from July 31, 2026.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all IKONISYS news